Print

Meet Active Biotech at BIO2005 Annual Convention, June 19-22 in Philadelphia, USA

2005-06-15

Active Biotech is a Swedish biotechnology company focusing on the development of pharmaceuticals. Active Biotech has a deep and diversified R&D portfolio with pipeline projects in clinical development in the areas of autoimmune/inflammatory diseases and cancer.
Most advanced projects are laquinimod (in partnership with Teva Pharmaceutical Industries Ltd.), an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® (in partnership with Avidex Ltd.) primarily for RA.
Active Biotech is exploring potential new partnerships for individual projects that are not yet partnered. The intention is to enter partnership agreements at the appropriate time with pharmaceutical companies for further clinical development and future commercialization.
Meet representatives from Active Biotech at June 19-22 in the area of Scandinavian Bioscience at the Swedish Pavilion, booth #2049.
Lund, June 15, 2005
Active Biotech AB (publ)
For further information about Active Biotech, please visit www.activebiotech.com.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50

pdf



Back